KIM
CRNX

Kestra Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Kestra Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-293
Closed -$8.43K – 495
2025
Q2 		$8.43K Sell
293
-2,546
-90% -$78.6K ﹤0.01% 557
2025
Q1 		$95.2K Buy
+2,839
New +$106K ﹤0.01% 429

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Kestra Investment Management's CRNX Position: Q3 2025 in Review

Kestra Investment Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 293 shares — an estimated $8.43K sold.

Kestra Investment Management first reported a position in CRNX in Q1 2025 and held it in 2 quarters. The position peaked at $95.2K in Q1 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Kestra Investment Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kestra Investment Management sold 293 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $8.43K.
  • Kestra Investment Management first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Kestra Investment Management's Crinetics Pharmaceuticals position peaked at $95.2K in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Kestra Investment Management's 13F filing for Q3 2025, filed 17 Nov 2025.